Sarepta Therapeutics, Inc. Q2 2026 Earnings Call Summary
Sarepta Therapeutics reported GAAP and non-GAAP operating profitability and said ELEVIDYS commercial execution improved enrollment forms. It narrowed 2026 total net product revenue guidance to $1.2B-$1.3B and expects second-half revenue modestly lower. The company recorded a $39M litigation contingency and raised collaboration/other revenue guidance by $75M on higher Roche contract manufacturing. Interim MAD results for FSHD (SRP-1001) and DM1 (SRP-1003) are expected in H2 2026.
How this was made
The 30-second read
Why it matters
Traders should update SRPT’s 2026 revenue expectations, second-half seasonality, and the catalyst calendar for MAD interim results and ENDEAVOR Cohort 8 12-week data.
Market read
The article contains concrete, tradable updates to SRPT’s 2026 revenue range, litigation contingency, and multiple pipeline milestone timings.
What to watch
The $39M litigation contingency and the ENDEAVOR Cohort 8 timing shift could be temporary noise, while the bigger swing factor may be whether MAD interim data supports the 'biological chain' narrative for accelerated pathways.
Background
This is a Q2 2026 earnings call summary focused on Sarepta’s ELEVIDYS commercial execution and its siRNA pipeline (including SRP-1001 and SRP-1003).
Ticker impact
Sarepta narrowed 2026 net product revenue guidance to $1.2B-$1.3B and pushed key MAD study readouts into 2H 2026 and Q1 2027.
Likely choppy trading around the guidance range and the updated milestone timing, with sentiment sensitive to enrollment-form improvement and 2027 inflection.
The article provides specific, decision-relevant updates: narrowed revenue guidance, second-half seasonality, a $39M litigation contingency, and concrete timing changes for ENDEAVOR Cohort 8 and MAD interim results.
Market effects
Reinforces competitive and regulatory uncertainty for siRNA platforms, with flexible accelerated versus traditional approval planning.
No clear regional spillover beyond US biotech sentiment.
Limited, aside from the Roche partnership contract manufacturing reference affecting broader biotech supply-chain expectations.
Counterpoint
The revenue guide is narrowed but management frames enrollment-form improvements as a 2027 driver, so near-term caution may be overdone if 2027 inflection is credible.
Key entities
- companySarepta Therapeutics
Guidance narrowed for 2026 net product revenue, with updated clinical and regulatory strategy details on the call.
- productELEVIDYS
Commercial strategy pivoted toward benefit-risk discussion; enrollment-form activity is cited as improving.
- programSRP-1001
MAD study interim results for FSHD expected in 2H 2026.
- programSRP-1003
MAD study interim results for DM1 expected in 2H 2026.
- clinical milestoneENDEAVOR Cohort 8
12-week data moved to Q1 2027 due to sequential dosing.
